BR112020016123A2 - compostos e composições terapêuticas - Google Patents

compostos e composições terapêuticas Download PDF

Info

Publication number
BR112020016123A2
BR112020016123A2 BR112020016123-3A BR112020016123A BR112020016123A2 BR 112020016123 A2 BR112020016123 A2 BR 112020016123A2 BR 112020016123 A BR112020016123 A BR 112020016123A BR 112020016123 A2 BR112020016123 A2 BR 112020016123A2
Authority
BR
Brazil
Prior art keywords
compound
individual
composition
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BR112020016123-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Bertrand L. Chenard
Yuelian Xu
Frans L. Stassen
Neil J. Hayward
Zhiyao Teng
Original Assignee
eXIthera Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by eXIthera Pharmaceuticals Inc. filed Critical eXIthera Pharmaceuticals Inc.
Publication of BR112020016123A2 publication Critical patent/BR112020016123A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112020016123-3A 2018-02-07 2019-02-04 compostos e composições terapêuticas BR112020016123A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862627435P 2018-02-07 2018-02-07
US62/627,435 2018-02-07
PCT/US2019/016503 WO2019156929A1 (en) 2018-02-07 2019-02-04 Therapeutic compounds and compositions

Publications (1)

Publication Number Publication Date
BR112020016123A2 true BR112020016123A2 (pt) 2021-02-23

Family

ID=67548561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020016123-3A BR112020016123A2 (pt) 2018-02-07 2019-02-04 compostos e composições terapêuticas

Country Status (10)

Country Link
US (2) US11691962B2 (https=)
EP (1) EP3749662A4 (https=)
JP (2) JP7397797B2 (https=)
KR (1) KR20200118088A (https=)
CN (1) CN111902404A (https=)
AU (1) AU2019217366B2 (https=)
BR (1) BR112020016123A2 (https=)
CA (1) CA3089970A1 (https=)
IL (2) IL276563B1 (https=)
WO (1) WO2019156929A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2733405C2 (ru) 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
CA3089970A1 (en) 2018-02-07 2019-08-15 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595532A (en) 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
JP2002501081A (ja) 1998-01-26 2002-01-15 ビーエーエスエフ アクチェンゲゼルシャフト トロンビンインヒビター
HUP0104308A3 (en) 1998-06-25 2002-06-28 Bristol Myers Squibb Co Amidino and guanidino azetidinone derivatives as tryptase inhibitors, process for their preparation, pharmaceutical compositions thereof and intermediates
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
EP1099690A4 (en) 1998-07-23 2001-10-17 Shionogi & Co MONOCYCLIC BETA LACTAM COMPOUNDS AND CHYMASE INHIBITORS THAT CONTAIN THEM
KR20060120601A (ko) 2003-08-22 2006-11-27 데이진 화-마 가부시키가이샤 키마제 저해제를 유효 성분으로서 함유하는 약제
EP1871741A4 (en) 2005-04-04 2012-01-11 Daiamed Inc SUBSTITUTED AZETIDINONE
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
JP5756800B2 (ja) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を調節するアゼチジン2−カルボキサミド誘導体
NZ602266A (en) 2010-02-11 2014-05-30 Bristol Myers Squibb Co Macrocycles as factor xia inhibitors
JP6033319B2 (ja) 2011-10-14 2016-11-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第XIa因子阻害剤としての置換テトラヒドロイソキノリン化合物
SG11201406142XA (en) 2012-03-27 2014-10-30 Univ Duke Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
RU2733405C2 (ru) * 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
US20190315711A1 (en) 2016-12-23 2019-10-17 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions
CA3089970A1 (en) 2018-02-07 2019-08-15 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
JP2022506110A (ja) 2018-10-30 2022-01-17 エクセセーラ ファーマシューティカルズ インコーポレイテッド 治療用化合物および組成物
CN113056263A (zh) 2018-10-30 2021-06-29 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物
JP2022523712A (ja) 2019-01-29 2022-04-26 エクセセーラ ファーマシューティカルズ インコーポレイテッド 治療用化合物および組成物

Also Published As

Publication number Publication date
AU2019217366A1 (en) 2020-08-20
US20240059670A1 (en) 2024-02-22
CA3089970A1 (en) 2019-08-15
US12152014B2 (en) 2024-11-26
WO2019156929A1 (en) 2019-08-15
JP2021512894A (ja) 2021-05-20
RU2020129237A (ru) 2022-03-09
IL276563A (en) 2020-09-30
JP7397797B2 (ja) 2023-12-13
AU2019217366B2 (en) 2024-07-11
EP3749662A4 (en) 2021-07-14
IL325484A (en) 2026-02-01
US20210188812A1 (en) 2021-06-24
KR20200118088A (ko) 2020-10-14
JP2024023490A (ja) 2024-02-21
CN111902404A (zh) 2020-11-06
IL276563B1 (en) 2026-01-01
EP3749662A1 (en) 2020-12-16
US11691962B2 (en) 2023-07-04

Similar Documents

Publication Publication Date Title
CA2938884C (en) Substituted azetidine compounds and their use as factor xia or kallikrein inhibitors
US20210261524A1 (en) Therapeutic compounds and compositions
JP2013121919A (ja) 血漿カリクレイン阻害剤
EA015942B1 (ru) Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
CN115605467B (zh) Phd抑制剂化合物、组合物和其用途
US12152014B2 (en) Therapeutic compounds and compositions
WO2018118705A1 (en) Therapeutic compounds and compositions
US20210253550A1 (en) Therapeutic compounds and compositions
RU2817800C2 (ru) Терапевтические соединения и композиции
RU2813780C2 (ru) Терапевтические соединения и композиции
HK1230083B (zh) 治療化合物和組合物

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 401/06 , C07D 405/14 , C07D 417/06

Ipc: C07D 401/06 (2006.01), C07D 405/14 (2006.01), C07D

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]